Yiqun Shellman
Concepts (320)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 34 | 2024 | 757 | 6.600 |
Why?
| | Skin Neoplasms | 15 | 2024 | 852 | 3.250 |
Why?
| | Sulfonamides | 7 | 2020 | 513 | 2.140 |
Why?
| | Neoplastic Stem Cells | 5 | 2021 | 399 | 1.990 |
Why?
| | Melanocytes | 9 | 2024 | 65 | 1.970 |
Why?
| | Apoptosis | 14 | 2018 | 2552 | 1.850 |
Why?
| | Nitrophenols | 5 | 2017 | 34 | 1.790 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 8 | 2021 | 233 | 1.760 |
Why?
| | Biphenyl Compounds | 5 | 2017 | 63 | 1.730 |
Why?
| | Antineoplastic Agents | 7 | 2024 | 2123 | 1.670 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 4 | 2024 | 41 | 1.500 |
Why?
| | MicroRNAs | 4 | 2020 | 692 | 0.960 |
Why?
| | Cell Line, Tumor | 23 | 2023 | 3406 | 0.930 |
Why?
| | Hair Color | 1 | 2024 | 15 | 0.890 |
Why?
| | Hyperpigmentation | 1 | 2024 | 26 | 0.870 |
Why?
| | Tankyrases | 1 | 2023 | 15 | 0.850 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2024 | 66 | 0.810 |
Why?
| | Cell Culture Techniques | 3 | 2021 | 362 | 0.810 |
Why?
| | Tumor Suppressor Proteins | 3 | 2024 | 327 | 0.760 |
Why?
| | GTP Phosphohydrolases | 2 | 2018 | 93 | 0.700 |
Why?
| | Proto-Oncogene Proteins | 2 | 2018 | 647 | 0.690 |
Why?
| | Spheroids, Cellular | 1 | 2021 | 76 | 0.660 |
Why?
| | Nevus | 1 | 2020 | 26 | 0.650 |
Why?
| | Aniline Compounds | 1 | 2020 | 102 | 0.640 |
Why?
| | Cell Survival | 7 | 2021 | 1116 | 0.550 |
Why?
| | Apoptosis Regulatory Proteins | 3 | 2018 | 188 | 0.540 |
Why?
| | Microtubule-Associated Proteins | 1 | 2018 | 194 | 0.540 |
Why?
| | Hepatitis B Antibodies | 1 | 2016 | 11 | 0.520 |
Why?
| | Immunity, Maternally-Acquired | 1 | 2016 | 19 | 0.520 |
Why?
| | Drug Therapy, Combination | 2 | 2016 | 1062 | 0.510 |
Why?
| | Drug Synergism | 5 | 2017 | 383 | 0.510 |
Why?
| | Hepatitis B virus | 1 | 2016 | 40 | 0.510 |
Why?
| | Genes, ras | 3 | 2008 | 97 | 0.500 |
Why?
| | Hepatitis B Vaccines | 1 | 2016 | 45 | 0.500 |
Why?
| | Mitochondrial Proteins | 1 | 2018 | 256 | 0.500 |
Why?
| | Lentigo | 1 | 2015 | 6 | 0.480 |
Why?
| | Fenretinide | 1 | 2014 | 4 | 0.460 |
Why?
| | Molecular Targeted Therapy | 2 | 2015 | 411 | 0.460 |
Why?
| | Antibody Formation | 1 | 2016 | 298 | 0.460 |
Why?
| | Hyperthermia, Induced | 2 | 2007 | 116 | 0.460 |
Why?
| | Oligopeptides | 1 | 2016 | 271 | 0.460 |
Why?
| | Piperazines | 5 | 2017 | 350 | 0.460 |
Why?
| | Xenograft Model Antitumor Assays | 5 | 2021 | 868 | 0.460 |
Why?
| | Peptide Fragments | 1 | 2018 | 705 | 0.440 |
Why?
| | Gene Expression Regulation, Neoplastic | 8 | 2020 | 1396 | 0.430 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2017 | 429 | 0.430 |
Why?
| | Down-Regulation | 3 | 2012 | 656 | 0.400 |
Why?
| | Cell Proliferation | 7 | 2017 | 2476 | 0.390 |
Why?
| | Mice | 13 | 2024 | 17759 | 0.380 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2011 | 121 | 0.370 |
Why?
| | Alkylating Agents | 1 | 2011 | 24 | 0.370 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2016 | 224 | 0.360 |
Why?
| | Dacarbazine | 1 | 2011 | 98 | 0.360 |
Why?
| | Biological Assay | 1 | 2011 | 123 | 0.360 |
Why?
| | Humans | 42 | 2024 | 136803 | 0.350 |
Why?
| | Biomimetic Materials | 1 | 2011 | 72 | 0.340 |
Why?
| | Mice, Nude | 5 | 2020 | 696 | 0.340 |
Why?
| | Animals | 17 | 2024 | 36850 | 0.310 |
Why?
| | Ultraviolet Therapy | 2 | 2020 | 16 | 0.310 |
Why?
| | Mutation | 8 | 2017 | 3947 | 0.310 |
Why?
| | Leupeptins | 1 | 2008 | 10 | 0.310 |
Why?
| | Vitiligo | 2 | 2020 | 42 | 0.310 |
Why?
| | Skin Pigmentation | 2 | 2020 | 49 | 0.300 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2008 | 49 | 0.300 |
Why?
| | Proteasome Inhibitors | 1 | 2008 | 46 | 0.300 |
Why?
| | Indoles | 1 | 2011 | 410 | 0.290 |
Why?
| | Saccharomyces cerevisiae | 5 | 2011 | 556 | 0.290 |
Why?
| | rho GTP-Binding Proteins | 2 | 2020 | 60 | 0.280 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2008 | 437 | 0.270 |
Why?
| | Caspases | 5 | 2017 | 247 | 0.270 |
Why?
| | Neurofibromin 1 | 2 | 2017 | 26 | 0.270 |
Why?
| | Membrane Proteins | 2 | 2016 | 1163 | 0.270 |
Why?
| | Cell Self Renewal | 2 | 2017 | 55 | 0.260 |
Why?
| | Transfection | 5 | 2012 | 941 | 0.260 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2006 | 56 | 0.250 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2006 | 132 | 0.240 |
Why?
| | Extracellular Matrix Proteins | 2 | 2006 | 153 | 0.240 |
Why?
| | Exome | 2 | 2017 | 230 | 0.240 |
Why?
| | Endoplasmic Reticulum | 1 | 2007 | 264 | 0.230 |
Why?
| | Lovastatin | 1 | 2005 | 37 | 0.230 |
Why?
| | Biotechnology | 1 | 2005 | 41 | 0.230 |
Why?
| | Biomarkers, Tumor | 4 | 2017 | 1272 | 0.220 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2018 | 800 | 0.220 |
Why?
| | Ankyrin Repeat | 1 | 2023 | 2 | 0.220 |
Why?
| | Poly ADP Ribosylation | 1 | 2023 | 10 | 0.220 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2006 | 366 | 0.210 |
Why?
| | Equipment Failure Analysis | 1 | 2004 | 131 | 0.210 |
Why?
| | Bcl-2-Like Protein 11 | 2 | 2017 | 38 | 0.210 |
Why?
| | Pedigree | 1 | 2024 | 514 | 0.200 |
Why?
| | Phenotype | 3 | 2024 | 3189 | 0.200 |
Why?
| | Specimen Handling | 1 | 2004 | 181 | 0.200 |
Why?
| | ras Proteins | 1 | 2003 | 153 | 0.200 |
Why?
| | Cell Lineage | 1 | 2024 | 347 | 0.190 |
Why?
| | Biophysics | 1 | 2022 | 69 | 0.190 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 10 | 0.190 |
Why?
| | Fungal Proteins | 2 | 1999 | 123 | 0.180 |
Why?
| | Hair Follicle | 2 | 2020 | 46 | 0.180 |
Why?
| | Hot Temperature | 1 | 2004 | 391 | 0.180 |
Why?
| | Cell Cycle Proteins | 3 | 2000 | 613 | 0.170 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2003 | 543 | 0.170 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2005 | 443 | 0.170 |
Why?
| | Positive Regulatory Domain I-Binding Factor 1 | 1 | 2020 | 18 | 0.170 |
Why?
| | Adult Stem Cells | 1 | 2020 | 39 | 0.170 |
Why?
| | Neoplasm Invasiveness | 3 | 2013 | 507 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2016 | 1058 | 0.160 |
Why?
| | CDC28 Protein Kinase, S cerevisiae | 1 | 1999 | 7 | 0.160 |
Why?
| | beta Catenin | 2 | 2020 | 253 | 0.150 |
Why?
| | Female | 14 | 2024 | 72816 | 0.150 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2024 | 913 | 0.150 |
Why?
| | Melanoma, Experimental | 2 | 2011 | 114 | 0.150 |
Why?
| | Dynamins | 1 | 2018 | 37 | 0.150 |
Why?
| | Ultraviolet Rays | 3 | 2008 | 390 | 0.150 |
Why?
| | Cytokines | 1 | 2006 | 2084 | 0.140 |
Why?
| | Cyclin-Dependent Kinases | 1 | 1999 | 132 | 0.140 |
Why?
| | Saccharomyces cerevisiae Proteins | 2 | 1999 | 404 | 0.140 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2017 | 25 | 0.140 |
Why?
| | Cancer Vaccines | 2 | 2011 | 172 | 0.140 |
Why?
| | Transforming Growth Factor beta | 1 | 2000 | 480 | 0.140 |
Why?
| | Zebrafish Proteins | 1 | 2020 | 286 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2017 | 67 | 0.130 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 53 | 0.130 |
Why?
| | Gene Knockout Techniques | 1 | 2017 | 117 | 0.130 |
Why?
| | Mucous Membrane | 1 | 2017 | 125 | 0.130 |
Why?
| | Genes, erbB-1 | 1 | 2016 | 17 | 0.130 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2016 | 80 | 0.130 |
Why?
| | Pyrroles | 1 | 2017 | 213 | 0.130 |
Why?
| | Disease Models, Animal | 3 | 2018 | 4282 | 0.130 |
Why?
| | Transcription, Genetic | 4 | 2017 | 1455 | 0.120 |
Why?
| | Zebrafish | 1 | 2020 | 495 | 0.120 |
Why?
| | Inflammasomes | 1 | 2017 | 128 | 0.120 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 214 | 0.120 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2011 | 528 | 0.120 |
Why?
| | Signal Transduction | 4 | 2020 | 5077 | 0.120 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2020 | 858 | 0.120 |
Why?
| | Phosphoproteins | 1 | 2017 | 337 | 0.110 |
Why?
| | Retinoids | 1 | 2014 | 33 | 0.110 |
Why?
| | Genetic Linkage | 1 | 2015 | 297 | 0.110 |
Why?
| | Machine Learning | 1 | 2020 | 488 | 0.110 |
Why?
| | Cells, Cultured | 4 | 2020 | 4192 | 0.110 |
Why?
| | Complementary Therapies | 1 | 2015 | 88 | 0.110 |
Why?
| | Caspase 3 | 2 | 2005 | 246 | 0.110 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2014 | 100 | 0.110 |
Why?
| | Prognosis | 3 | 2020 | 4013 | 0.110 |
Why?
| | Genes, Tumor Suppressor | 1 | 2013 | 86 | 0.100 |
Why?
| | Neoplasm Metastasis | 2 | 2013 | 657 | 0.100 |
Why?
| | Genomic Instability | 1 | 2013 | 53 | 0.100 |
Why?
| | Stem Cells | 1 | 2017 | 592 | 0.100 |
Why?
| | Up-Regulation | 2 | 2006 | 844 | 0.100 |
Why?
| | Smad1 Protein | 1 | 2012 | 18 | 0.100 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2013 | 69 | 0.100 |
Why?
| | Neoplasm Proteins | 2 | 2007 | 434 | 0.100 |
Why?
| | Microarray Analysis | 1 | 2012 | 116 | 0.100 |
Why?
| | BRCA1 Protein | 1 | 2013 | 76 | 0.100 |
Why?
| | Alcohol Oxidoreductases | 1 | 2013 | 62 | 0.100 |
Why?
| | Tretinoin | 1 | 2013 | 123 | 0.100 |
Why?
| | Adult | 6 | 2024 | 37643 | 0.100 |
Why?
| | Biomedical Research | 1 | 2018 | 688 | 0.090 |
Why?
| | Survival Analysis | 1 | 2015 | 1321 | 0.090 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 301 | 0.090 |
Why?
| | Cellular Senescence | 1 | 2013 | 187 | 0.090 |
Why?
| | Disease Progression | 5 | 2020 | 2751 | 0.090 |
Why?
| | Male | 6 | 2024 | 67330 | 0.090 |
Why?
| | Annexin A5 | 2 | 2013 | 25 | 0.090 |
Why?
| | Vaccines, Synthetic | 1 | 2011 | 126 | 0.090 |
Why?
| | Genetic Engineering | 1 | 2011 | 91 | 0.080 |
Why?
| | Time Factors | 3 | 2013 | 6809 | 0.080 |
Why?
| | Cell Death | 1 | 2011 | 372 | 0.080 |
Why?
| | RNA Interference | 2 | 2009 | 466 | 0.080 |
Why?
| | Aldose-Ketose Isomerases | 1 | 2009 | 6 | 0.080 |
Why?
| | Treatment Outcome | 3 | 2020 | 10748 | 0.080 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2009 | 86 | 0.080 |
Why?
| | Precipitin Tests | 2 | 1999 | 100 | 0.080 |
Why?
| | Protein Structure, Tertiary | 1 | 2011 | 860 | 0.080 |
Why?
| | Adenocarcinoma | 1 | 2016 | 938 | 0.080 |
Why?
| | Methionine | 1 | 2009 | 160 | 0.070 |
Why?
| | Antioxidants | 2 | 2013 | 584 | 0.070 |
Why?
| | Anoikis | 1 | 2008 | 31 | 0.070 |
Why?
| | Biomarkers | 1 | 2020 | 4145 | 0.070 |
Why?
| | Cell Line, Transformed | 1 | 2008 | 145 | 0.070 |
Why?
| | Microphthalmia-Associated Transcription Factor | 1 | 2008 | 14 | 0.070 |
Why?
| | Radiation-Protective Agents | 1 | 2008 | 26 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2052 | 0.070 |
Why?
| | Heat-Shock Proteins | 1 | 2007 | 142 | 0.070 |
Why?
| | Cysteine | 1 | 2008 | 204 | 0.060 |
Why?
| | rhoC GTP-Binding Protein | 1 | 2006 | 6 | 0.060 |
Why?
| | Enzyme Induction | 1 | 2006 | 90 | 0.060 |
Why?
| | Growth Substances | 1 | 2006 | 147 | 0.060 |
Why?
| | Models, Animal | 1 | 2008 | 384 | 0.060 |
Why?
| | Molecular Chaperones | 1 | 2007 | 195 | 0.060 |
Why?
| | Young Adult | 3 | 2020 | 13129 | 0.060 |
Why?
| | Acridine Orange | 1 | 2005 | 3 | 0.060 |
Why?
| | Ethidium | 1 | 2005 | 6 | 0.060 |
Why?
| | Risk Assessment | 1 | 2015 | 3434 | 0.060 |
Why?
| | Caspase 7 | 1 | 2005 | 22 | 0.060 |
Why?
| | Dimethylallyltranstransferase | 1 | 2005 | 1 | 0.060 |
Why?
| | Polyisoprenyl Phosphates | 1 | 2005 | 5 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1501 | 0.060 |
Why?
| | In Situ Nick-End Labeling | 1 | 2005 | 124 | 0.060 |
Why?
| | Pravastatin | 1 | 2005 | 41 | 0.060 |
Why?
| | Jurkat Cells | 1 | 2005 | 134 | 0.060 |
Why?
| | False Positive Reactions | 1 | 2005 | 115 | 0.060 |
Why?
| | Sesquiterpenes | 1 | 2005 | 55 | 0.060 |
Why?
| | Antigens, Neoplasm | 1 | 2007 | 319 | 0.060 |
Why?
| | Infant, Newborn | 1 | 2016 | 6032 | 0.060 |
Why?
| | Camptothecin | 1 | 2005 | 115 | 0.060 |
Why?
| | Necrosis | 1 | 2005 | 245 | 0.050 |
Why?
| | Prospective Studies | 1 | 2016 | 7573 | 0.050 |
Why?
| | Transcriptional Activation | 1 | 2006 | 378 | 0.050 |
Why?
| | Molecular Sequence Data | 3 | 2009 | 2894 | 0.050 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2005 | 190 | 0.050 |
Why?
| | Reproducibility of Results | 1 | 2011 | 3265 | 0.050 |
Why?
| | Cell Adhesion | 1 | 2005 | 466 | 0.050 |
Why?
| | Feedback | 1 | 2004 | 172 | 0.050 |
Why?
| | Gene Expression | 2 | 2017 | 1500 | 0.050 |
Why?
| | Pregnancy | 1 | 2016 | 6729 | 0.050 |
Why?
| | Fluorescent Dyes | 1 | 2005 | 317 | 0.050 |
Why?
| | Anticholesteremic Agents | 1 | 2005 | 153 | 0.050 |
Why?
| | Lung Neoplasms | 1 | 2016 | 2489 | 0.050 |
Why?
| | Cell Hypoxia | 1 | 2003 | 226 | 0.050 |
Why?
| | Equipment Design | 1 | 2004 | 521 | 0.050 |
Why?
| | Infant | 1 | 2016 | 9395 | 0.050 |
Why?
| | Inflammation | 1 | 2013 | 2835 | 0.050 |
Why?
| | fas Receptor | 1 | 2002 | 95 | 0.050 |
Why?
| | Interleukin-1 | 1 | 2006 | 964 | 0.050 |
Why?
| | Cell Division | 2 | 2002 | 796 | 0.050 |
Why?
| | Tumor Cells, Cultured | 2 | 2002 | 953 | 0.050 |
Why?
| | Mitochondria | 1 | 2008 | 946 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2005 | 839 | 0.050 |
Why?
| | Substrate Specificity | 2 | 1999 | 371 | 0.050 |
Why?
| | Proteomics | 2 | 2009 | 1109 | 0.040 |
Why?
| | Chromatin | 1 | 2005 | 519 | 0.040 |
Why?
| | Temperature | 1 | 2004 | 675 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2006 | 1242 | 0.040 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2023 | 340 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2009 | 2138 | 0.040 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2023 | 610 | 0.040 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2020 | 50 | 0.040 |
Why?
| | MART-1 Antigen | 2 | 2011 | 12 | 0.040 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2005 | 683 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2002 | 455 | 0.040 |
Why?
| | Chromatography, Ion Exchange | 1 | 1999 | 54 | 0.040 |
Why?
| | Chromatography, Affinity | 1 | 1999 | 88 | 0.040 |
Why?
| | Keratinocytes | 1 | 2020 | 248 | 0.040 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2011 | 225 | 0.040 |
Why?
| | Hybrid Cells | 1 | 1998 | 49 | 0.040 |
Why?
| | Genetic Complementation Test | 1 | 1998 | 66 | 0.040 |
Why?
| | Cyclins | 1 | 1999 | 91 | 0.040 |
Why?
| | Cell Movement | 1 | 2023 | 968 | 0.040 |
Why?
| | Immunoblotting | 1 | 1999 | 306 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2003 | 2831 | 0.040 |
Why?
| | Pigmentation | 1 | 2018 | 52 | 0.040 |
Why?
| | Molecular Weight | 1 | 1998 | 335 | 0.040 |
Why?
| | Laser Capture Microdissection | 1 | 2017 | 33 | 0.040 |
Why?
| | NLR Proteins | 1 | 2017 | 8 | 0.030 |
Why?
| | Protein Kinases | 1 | 1999 | 319 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2017 | 257 | 0.030 |
Why?
| | Cell Cycle | 1 | 1999 | 601 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2017 | 403 | 0.030 |
Why?
| | Tumor Burden | 1 | 2017 | 309 | 0.030 |
Why?
| | Phosphorylation | 1 | 2000 | 1758 | 0.030 |
Why?
| | Survival Rate | 1 | 2020 | 1964 | 0.030 |
Why?
| | Middle Aged | 4 | 2020 | 33239 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 182 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2016 | 399 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2017 | 452 | 0.030 |
Why?
| | Monophenol Monooxygenase | 1 | 2013 | 8 | 0.030 |
Why?
| | Microscopy, Phase-Contrast | 1 | 2013 | 18 | 0.030 |
Why?
| | Melanins | 1 | 2013 | 18 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 535 | 0.030 |
Why?
| | Spectrophotometry | 1 | 2013 | 60 | 0.030 |
Why?
| | Aged | 3 | 2020 | 23808 | 0.030 |
Why?
| | Catalase | 1 | 2013 | 130 | 0.030 |
Why?
| | Administration, Topical | 1 | 2013 | 149 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2020 | 1982 | 0.020 |
Why?
| | DNA, Neoplasm | 1 | 2013 | 164 | 0.020 |
Why?
| | Precision Medicine | 1 | 2016 | 426 | 0.020 |
Why?
| | Computational Biology | 1 | 2016 | 643 | 0.020 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 346 | 0.020 |
Why?
| | DNA Repair | 1 | 2013 | 231 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2000 | 2605 | 0.020 |
Why?
| | DNA Damage | 1 | 2013 | 420 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3540 | 0.020 |
Why?
| | S-Adenosylmethionine | 1 | 2009 | 54 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2009 | 194 | 0.020 |
Why?
| | Mice, Inbred C57BL | 2 | 2011 | 5750 | 0.020 |
Why?
| | Mice, Hairless | 1 | 2008 | 60 | 0.020 |
Why?
| | Molecular Structure | 1 | 2009 | 489 | 0.020 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2007 | 41 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5106 | 0.020 |
Why?
| | Histones | 1 | 2013 | 636 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 810 | 0.020 |
Why?
| | 3' Untranslated Regions | 1 | 2008 | 145 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2007 | 152 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 2008 | 523 | 0.020 |
Why?
| | Genome, Human | 1 | 2008 | 423 | 0.010 |
Why?
| | Spleen | 1 | 2007 | 514 | 0.010 |
Why?
| | Kaplan-Meier Estimate | 1 | 2007 | 888 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2017 | 7593 | 0.010 |
Why?
| | Alleles | 1 | 2008 | 890 | 0.010 |
Why?
| | Base Sequence | 1 | 2008 | 2179 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2007 | 1350 | 0.010 |
Why?
| | Interferon-gamma | 1 | 2007 | 789 | 0.010 |
Why?
| | Cathepsin D | 1 | 2003 | 18 | 0.010 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2002 | 22 | 0.010 |
Why?
| | Fas Ligand Protein | 1 | 2002 | 59 | 0.010 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2003 | 382 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2007 | 1095 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 21385 | 0.010 |
Why?
| | Protein Processing, Post-Translational | 1 | 2003 | 465 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2008 | 1772 | 0.010 |
Why?
| | Receptors, Cell Surface | 1 | 2002 | 382 | 0.010 |
Why?
| | Child | 1 | 2020 | 21819 | 0.010 |
Why?
| | Mass Spectrometry | 1 | 2003 | 738 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 500 | 0.010 |
Why?
| | Apc6 Subunit, Anaphase-Promoting Complex-Cyclosome | 1 | 1999 | 1 | 0.010 |
Why?
| | Vaccination | 1 | 2007 | 1377 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 2003 | 712 | 0.010 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 1999 | 126 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2002 | 769 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 1999 | 664 | 0.010 |
Why?
|
|
Shellman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|